Vatalanib succinate

• CAT Number: I011272
• CAS Number: 212142-18-2
• Molecular Formula: C24H21ClN4O4
• Molecular Weight: 464.91
• Purity: ≥95%
• Synonyms: Alternative Names: CGP 79787D, PTK787/ZK222584
• Target: VEGFR
• Solubility: Soluble to 100 mM in DMSO
• Storage: Store at -20C
• IUPAC Name: butanedioic acid;N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine
• InChI: InChI=1S/C20H15ClN4.C4H6O4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14;5-3(6)1-2-4(7)8/h1-12H,13H2,(H,23,25);1-2H2,(H,5,6)(H,7,8)
• InChIKey: LLDWLPRYLVPDTG-UHFFFAOYSA-N
• SMILES: C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4.C(CC(=O)O)C(=O)O

Vatalanib succinate（Cat No.:I011272）is an oral, small-molecule tyrosine kinase inhibitor that targets vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), and c-kit, all of which play key roles in angiogenesis and tumor growth. By inhibiting these receptors, vatalanib impedes the formation of new blood vessels, thereby limiting the supply of nutrients to tumors. It has been investigated primarily for use in the treatment of various cancers, including solid tumors and metastatic disease. Clinical trials have shown promising results, but further studies are necessary to confirm its overall efficacy and safety.